Biosimilars are key alternatives for costly Biologics therapies and saving million dollars of patients in multiple diseases. Hence physicians are likely to adopt biosimilars “a reference product to biologics” which […]readmore
Tags : Events
In the last 20 years the global Biopharma space has changed a lot with ups and downs of companies and their growth. This analysis has found the multiple acquisitions and […]readmore